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Abstract

Author Manuscript

This study aimed to assess safety and therapeutic potential of gene electrotransfer as a method for
delivery of plasmid encoding vascular endothelial growth factor A to ischemic myocardium in a
porcine model. Myocardial ischemia was induced by surgically occluding the left anterior
descending coronary artery in swine. Gene electrotransfer following plasmid encoding vascular
endothelial growth factor A injection was performed at four sites in the ischemic region. Control
groups either received injections of the plasmid without electrotransfer or injections of saline
vehicle. Animals were monitored for seven weeks and hearts were evaluated for angiogenesis,
myocardial infarct size, and left ventricular contractility. Arteriograms suggest growth of new
arteries as early as two weeks post treatment in electrotransfer animals. There is a significant
reduction of infarct area and left ventricular contractility is improved in gene electrotransfer
treated group compared to controls. There was no significant difference in mortality of animals
treated with gene electrotransfer of plasmid encoding vascular endothelial growth factor A from
control groups. Gene delivery of plasmid encoding vascular endothelial growth factor A to
ischemic myocardium in a porcine model can be accomplished safely with potential for
myocardial repair and regeneration.
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Introduction

Author Manuscript

Heart disease is the leading cause of death in the United States accounting for a quarter of all
deaths 1, 2. Approximately 22% of men and 46% of women surviving myocardial infarction
will develop congestive heart failure within six years post MI 1-3. Of those diagnosed with
heart failure, the five year survival rate is only 50% 1-3. Extensive atherosclerosis of the
coronary arteries can lead to sufficient blockage of the coronary vessels to cause
downstream ischemia in the ventricles of the heart 4. Therefore, current clinical therapies
aim at direct revascularization to improve the survival rates for patients post MI 5. However,
the myocardium does not regenerate to its former electrical, histological, and functional
pumping potential 1, 6. Rather, ischemic myocardium remodels with fibroblast proliferation,
collagen deposition replacing cardiomyocytes, resulting in thin, non-contracting patches in
the ventricle, limiting cardiac output 7. There is little clinical evidence of return of viable
cardiomyoctes in patients surviving MI 6-8.

Author Manuscript

Due to atherosclerosis, angiogenesis in ischemic myocardium is likely impaired. There are
many pre-clinical therapies aimed at inducing angiogenesis in ischemic myocardium.
Vascular endothelial growth factor A (VEGF-A) is a commonly used gene for therapeutic
angiogenesis in coronary artery disease models, with intentions of collateral vessel
development in hypoxic areas 6. The primary role of VEGF-A is induction of angiogenesis
by stimulation of endothelial cells to migrate and proliferate in hypoxic areas 9-11. VEGF-A
also plays an important role in stem cell mobilization and differentiation to cardiomyocytes
as well as cardiomyocyte proliferation 12-15. VEGF-A promotes embryonic stem cell
differentiation into cardiomyocytes in a mouse model 14 and has been shown to promote
cardiac stem/progenitor cell mobilization and cardiomyocyte differentiation 12 and
cardiomyocyte proliferation 13. In addition to the use of VEGF-A delivered in the form of
recombinant protein, several gene therapy approaches for VEGF-A delivery to the
myocardium have also been evaluated 6.
Primary methods of gene delivery are viral mediated transfer and plasmid-based transfer.
Adenoviral vectors and adeno-associated (AAV) vectors are the most commonly used
vectors for delivery to the heart with immunogenicity and toxicity as major side effects.
Plasmid DNA delivery is associated with fewer side effects, low immune response, low
toxicity, and reduced cost but with lower efficiency 6, 16, 17.

Author Manuscript

There are several studies reported on electroporation aka gene electrotransfer (GET)
mediated gene delivery to the beating heart in a small animal model 18, 19. In our previous
studies we reported on plasmid DNA delivery via GET to cardiac muscle in vivo in a
porcine model 20, 21. GET of plasmid DNA can be applied safely directly to the ischemic
and non-ischemic myocardium and gene expression can be modulated by pulsing
conditions 20, 21. We have also determined that there may be a therapeutic benefit to local
delivery of pVEGF-A to ischemic myocardium, with improved myocardial perfusion two
weeks after treatment 21.
Our current study is focused on long-term outcome of GET delivery of pVEGF-A to
ischemic myocardium. We demonstrate that seven weeks post treatment new arteries can be
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observed in arteriograms in the majority of treated ischemic porcine hearts. We also
observed a reduction of myocardial damage from ischemic injury at treatment sites, with
improved contractility and relaxation of the left ventricular myocardium under chemically
induced stress. Overall, our results indicate a potential long-term therapeutic benefit of
exogenous VEGF-A gene delivery mediated by electrotransfer to ischemic myocardium,
with reduced progression to pathological cardiac remodeling at treatment sites in a porcine
model of myocardial infarction.

Results
Occlusion of Left Anterior Descending Coronary Artery leads to Myocardial Infarction of
Anterior Left Ventricle

Author Manuscript

To study the effects of an angiogenic therapy for myocardial infarction, we first confirmed
the presence of myocardial infarction of the anterior left ventricle after occlusion of the left
anterior descending (LAD) coronary artery. Thrombosis in myocardial infarction (TIMI)
scoring of the arterial tree, confirmed successful permanent occlusion of the LAD coronary
artery (Figure 1A). There were two animals that were excluded from the study, based on a
TIMI score of 3, indicating insufficient occlusion, and lack of ischemia (which was
confirmed at 7 weeks, with lack of MI detectable by triphenyltetrazolium (TTC) staining).
SPY® System analysis indicates a presence of a consistent ischemic region in terms of size
and drop in perfusion (Figure 1B and 1C). Further analysis of plasma indicated a sharp
increase of cardiac troponin-I 24 hours after the induction of ischemia indicating presence of
myocardial infarction (Supplemental Table 1). There is a sharp increase of plasma creatine
kinase muscle-isoform (CK-MM), indicating muscle cell damage and also consistent with
myocardial infarction in all groups (Supplemental Table 1).

Author Manuscript

GET of pVEGF-A to the ischemic myocardium has no deleterious effects on survival or
cardiac output in a porcine model

Author Manuscript

Kaplan-Meier log ranks survival analysis was performed on all animals surviving the onset
of acute ischemia and receiving GET with pVEGF-A, pVEGF-A injections without
electrotransfer, or saline injections. Two animals were excluded from the study due to
irreversible ventricular fibrillation following the occlusion of the left anterior descending
coronary artery prior to any experimental treatment. Two additional animals were excluded
due to lack of sufficient occlusion (TIMI score of 3), resulting in unabated flow through the
coronary artery, thus insufficient ischemia and no myocardial infarction. There was no
significant difference in survival between treated groups and untreated controls (Figure 2A),
indicating no significant increase of mortality due to electrotransfer mediated gene delivery
of VEGF-A encoding plasmid DNA to ischemic myocardium seven weeks post induction of
ischemia.
Measurements of left ventricular diameters via echocardiography indicate no significant
difference in calculated end-systolic and end-diastolic measures of volumes, ejection
fraction, fractional shortening and cardiac output between GET treated, pVEGF-A injection
without electrotransfer and sham control groups at any time point throughout the study
(Figure 2B-F), indicating no additional damage caused by GET mediated pVEGF-A to
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ischemic myocardium of the left ventricle. Other cardiac ultrasound parameters are also
consistent with this observation (Supplemental Figure 1).
GET of VEGF-A induces angiogenesis in ischemic myocardium in a porcine model
Arteriograms taken prior to LAD coronary artery occlusion were compared to arteriograms
taken two and seven weeks after LAD coronary artery occlusion and gene therapy treatment.
More than 70% of GET treated animals developed new arteries large enough to be visible
via arteriogram of the heart, while only 25% and 40% of the pVEGF-A injection only and
saline injection controls, respectively, developed new vessels (Figure 3A and 3B). The
average length of new vessels as visible in arteriograms was not significantly different
between treatment groups for animals that did have new vessel growth (Supplemental Figure
2).

Author Manuscript

Histological comparison of vessel density in ten randomly selected fields of view from
treatment sites indicate no significant difference in blood vessel density between the groups
seven weeks after induction of myocardial infarction and gene therapy treatment (Figure 3C
and 3D).
GET of pVEGF-A reduces myocardial damage from ischemic injury at treatment sites of the
left ventricle

Author Manuscript

Myocardial infarction caused by occlusion of the LAD coronary artery extended through the
anterior left ventricle, septum and right ventricle in most animals, based on TTC staining
performed on harvested hearts seven weeks post LAD coronary artery occlusion and gene
therapy treatment (Supplemental Figure 3). The infarct/ischemic area in the left ventricle
post LAD occlusion is significantly lower in GET of pVEGF-A group than the saline
injection group and is lower than the pVEGF-A injection without electrotransfer (4B).
Therefore, the infarct size in GET with pVEGF-A group at the treatment sites is smaller than
the infarct size of the control groups.
The total volume of myocardial infarction was not significantly different between the
experimental groups (Figure 4A). There is notable variability in the extent of the infarction
into the right ventricle and septum, which were untreated affecting the total size of the
infarct (Supplemental Figure 3).
GET of pVEGF-A improves left ventricular contractility and relaxation under dobutamine
stress

Author Manuscript

While the heart rate of all animals irrespective of the treatment group increased dramatically
in response to dobutamine administration, the change in intra-ventricular pressure correlated
inversely with total size of infarct in the left ventricle. Higher ventricular compliance was
observed for GET (n=2) treated hearts than controls (n=3), based on higher ±dP/dtmax
measurements as indicators of contractility and relaxation in response to increasing
dobutamine dose (Supplemental Figure 4).
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Discussion
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Atherosclerosis of coronary arteries with stable or unstable atherosclerotic plaques often
leads to ischemia of the myocardium or acute myocardial infarction respectively. Sufficient
hypoxic conditions result in loss of cardiomyocytes and remodeling of the myocardium into
non-contractile scar tissue. Sufficient loss of contractile function of the heart leads to heart
failure and reduced long-term survival. Restoration of blood flow is a common strategy for
clinical treatments such as coronary artery bypass grafting (CABG), however such
procedures do not address the problem of atherosclerosis. Autologous blood vessels (ex.
saphenous vein), often used for bypassing blocked arteries suffer the same atherosclerotic
disease as the original vessels, can and often do develop atherosclerotic plaques. An
angiogenic therapy is an attractive option due to the potential to alleviate ischemia in short
term and to cultivate new autologous vessels, which are not yet effected by atherosclerosis,
similar to blood vessels of younger individuals, who are not likely to suffer from
atherosclerosis. Here, we demonstrate an angiogenic gene therapy approach that results in
development of new arteries in ischemic myocardium with minimal adverse effects.
Our gene delivery approach is non-viral and non-integrating with temporary elevation of
local gene expression up to two weeks 21. We injected naked plasmid DNA encoding human
VEGF-A to four sites in the ischemic myocardium in a porcine animal model, followed by
electrotransfer. In our previous studies we have shown that GET greatly enhances gene
expression of VEGF-A compared to plasmid DNA injection without electrotransfer in a
porcine model of myocardial infarction. Here, we evaluated long term impact of GET
mediated delivery of pVEGF-A on ischemic myocardium.

Author Manuscript

The occlusion of the LAD coronary artery resulted in consistent ischemia of the left
ventricle in terms of the area affected and drop in perfusion observed, both measured with
SPY perfusion analysis system. There were no significant differences between ischemia of
the left ventricle between the groups of animals. Ischemia of the septum and the right
ventricle were not assessed, due to limitations of the SPY imaging system. Only the apical
surface of the left ventricle is visible via the SPY system, thus only perfusion through that
area can be assessed before and after the occlusion. Elevated plasma levels of cardiac
troponin I and CK-MM one day after LAD coronary artery occlusion indicated that
induction of ischemia also resulted in myocardial infarction. Therefore, the occlusion of the
LAD coronary artery resulted in consistent ischemia and acute myocardial infarction for all
treatment groups.

Author Manuscript

Seven-week survival was evaluated with the Kaplan-Meier log-rank evaluation. Mortality
was not significantly different between the treatment groups, indicating that GET of VEGFA did not adversely effect survival, or increase mortality compared to sham in DNA
injection only groups. This finding is consistent with our previous studies, indicating that
proper administration of electric pulses for gene therapy during the rise of the R-wave, does
not increase mortality, neither does overexpression of pVEGF-A at treatment sites of
ischemic myocardium. Therefore, the GET of pVEGF-A can be safely administered to
ischemic myocardium as a potential therapeutic.
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Echocardiography evaluation of ejection fraction, fractional shortening, end-systolic and end
diastolic volumes, cardiac output, and hypertrophy, indicates no significant difference
between treatment groups at any time points of the study. The occlusion distal to the second
diagonal branch, resulted in a relatively mild form of ischemia leading to low mortality and
allowing for evaluation of treatment effects. Variability in ischemia to the septum and the
right ventricle, may play a role in lack of significant differences in end-systolic and enddiastolic diameters and calculated volumes, ejection fraction and cardiac output measures
between the groups. Increase in cardiac output, end-systolic and end-diastolic volume at
seven weeks compared to the pre myocardial infarction values can also be caused by growth
of the entire animal and the heart, since most animals grew throughout the duration of the
study. Significantly, however, there were no adverse effects observed via echocardiography
in GET of VEGF-A treated animals compared to the control animals, indicating safety of the
treatment.

Author Manuscript
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While damage to the myocardium from ischemia occurs within hours of the onset of
ischemia, with some indication that necrosis of cardiomyocytes can also start within hours
after onset of ischemia, angiogenesis is not induced in the remodeling myocardium until
about 2-3 weeks from MI onset, with maturation of the new vessels taking even longer 26.
An angiogenic therapy with an onset earlier than what happens during the endogenous
course of remodeling of ischemic myocardium, may prove to be extremely beneficial
therapeutically. Here, we note the presence of new arteries in the distal regions of the
ischemic myocardium as early as 2 weeks after occlusion of the LAD coronary artery
(Figure 3). Arteriogram analysis (Figure 3A-B) indicates presence of arteries distal to the
location of the occlusion in the left ventricle. These vessels were not present in the arterial
tree of the same hearts prior to occlusion and treatment, indicating angiogenesis in more
than 70% of the hearts treated with GET of pVEGF-A at seven weeks. In comparison only
~25% and ~40% of the hearts treated with injection of pVEGF-A or saline, respectively,
developed new arteries in the same time frame (Figure 3B). Arteriograms can only detect
macroscopically sized vessels with radiopaque dye, thus onset of angiogenesis is actually
earlier than two weeks, in order to observe functional arteries via arteriogram analysis
(Figure 3A-B). Also, due to the size (approximately 0.5-1mm inner diameter) and abundant
perfusion of the detected arteries it is likely that these new collateral arteries are mature and
efficient.

Author Manuscript

Histological analysis for blood vessel density was only performed at seven weeks, for
observation of long-term effects of GET of pVEGF-A on the myocardium (Figure 3C). By
seven weeks vessel density at treated sites is indistinguishable between the gene therapy
group and corresponding controls (Figure 3C-D). Based on our previous data 21, exogenous
gene expression is expected to persist for up to two weeks, therefore homeostatic processes
are expected to take over after exogenous gene expression subsides. Blood vessel density
generally depends on oxygen requirements of the tissue 27, therefore once hypoxic
conditions and/or exogenous growth factors no longer drive angiogenesis, it is likely that the
tissue no longer requires angiogenic processes. This is consistent with our results of similar
blood vessel density on the microscopic level at 7 weeks after LAD coronary artery
occlusion and gene therapy application.
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VEGF-A has a well-known role in angiogenesis in response to hypoxic conditions, however
there are also multiple reports of VEGF-A promotion of cardiomyocyte proliferation as well
as induction of differentiation of cardiac progenitor cells or cardiac stem cells into
cardiomyocytes. Evaluation of the total size of the infarct including the myocardium of the
right ventricle, septum and left ventricle yielded no significant differences between treatment
groups, however there was considerable variability in the degree to which the right ventricle
and the septum were effected by LAD coronary artery occlusion (Supplemental Figure 3),
with some hearts having larger or smaller infarcts in those regions. Neither the right
ventricle nor septum was evaluated for ischemia prior to treatment with SPY analysis. These
regions contained no treatment sites, thus the variability in myocardial infarct size in these
regions is not due to treatment group (Figure 4A). This variability may also account for little
distinction between treatment groups via seven-week echocardiography evaluation (Figure
2B-2F and Supplemental Figure 1). Therefore, we evaluated ischemia and infarct size of the
left ventricle separately from other infarcted regions in order to assess the effect of GET of
VEGF-A at the treatment sites. Treatment sites were only present in the left ventricle. There
was a significant decrease in infarct size in terms of surface area of infarct at seven weeks
relative to the initial area of ischemia of the left ventricle, which is the site of GET treatment
(Figure 4B). The reduction of myocardial infarct area of the left ventricle was larger in the
GET of VEGF-A group than the pVEGF-A injection only, or the saline injection (sham)
control groups. The difference between GET and sham group is statistically significant
(p=0.0349), implicating a therapeutic potential for GET of pVEGF-A treatment.

Author Manuscript

A strong correlation between the presence of new arteries and reduction of infarct area was
not observed, suggesting another role for exogenous VEGF-A in repair of the myocardium
after ischemic injury. VEGF-A may preserve viability of resident cardiomyocytes, induce
cardiomyocyte proliferation in adjacent normoxic regions, promote migration and
differentiation of cardiac stem/progenitor cells to cardiomyocytes, or a combination of these
three. It has been noted that VEGF-A is capable of promoting proliferation of
cardiomyocytes 13, and induction of differentiation of cardiac stem cells or progenitor cells
to cardiomyocytes 15. This role of VEGF-A may account for the reduction of myocardial
infarct size in vivo with recruitment of new cardiomyocytes to the hypoxic myocardium in
addition to the traditional angiogenic role.

Author Manuscript

Ventricular contractility and relaxation are extremely important to quality of life. The ability
of the heart to respond to increased demand in oxygen due to stress such as exercise
determines patients’ daily physical abilities. Therefore, we evaluated contractility and
relaxation of infarcted hearts under increasing dobutamine stress seven weeks after
treatment. GET treated animals had a higher contractility and relaxation in response to
increased stress than the controls (Supplemental Figure 4A-B). While our sample size is
very limited, these results are consistent with our other findings, that there are more
contractile cells present in the treated left ventricles, leading to improved contractility of the
left ventricle in the treated groups, compared to control groups.
In summary, gene electrotransfer of VEGF-A encoding plasmid applied to left ventricular
ischemic myocardium has no deleterious effects on long term survival compared to injection
of VEGF-A encoding plasmid without electrotransfer, or injection of saline. There is no
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significant difference in echocardiographic measures between treatment groups at any time
point, possibly due to initial variation in ischemia to the septum and the right ventricle. The
proportion of animals with new arteries is much higher in GET group than in any of the
control groups as early as two weeks and persisting through seven weeks post treatment. By
seven weeks, there is no difference in blood vessel density between treatment groups at the
sites of treatment on the microscopic level. Overall myocardial infarct size is not
significantly different between treatment groups, however there is a difference in reduction
of left ventricular area of infarct. Myocardial infarct area reduction in GET group is
significantly larger, indicating a potential therapeutic benefit for this gene therapy approach.
Improved left ventricular contractility and relaxation under dobutamine stress further
support therapeutic application potential of GET of pVEGF-A to ischemic myocardium for
increasing angiogenesis and myocardial repair and regeneration. This study supports safety
and therapeutic potential for using gene electrotransfer to deliver plasmid DNA encoding
VEGF-A to ischemic myocardium in a porcine model.

Author Manuscript

Methods
Animals

Author Manuscript

Thirty-seven adult Yorkshire pigs were purchased from Bellview Farms, Smithville, Virginia
at an approximate weight of 31-47kg. All experimental studies followed an approved Old
Dominion University’s Institutional Animal Care and Use Committee protocol, in
accordance with the Guide for the Care and Use of Laboratory Animals at an AAALACaccredited facility, including a 12:12-hour light cycle. An ACLAM board certified
veterinarian determined all animals were free of disease through the use of health
examinations. Animals were quarantined and acclimated for a 7-day period before any
procedures were conducted. In addition, an echocardiography exam was conducted on each
animal to obtain baseline measures of cardiac health.
Plasmid
A commercially prepared plasmid, pVax1-hVEGF165(pVEGF-A), was used for these studies
(Aldevron, Fargo, ND). DNA was suspended in sterile saline at 2mg/ml. Endotoxin levels
were <0.1 EU/μg plasmid, confirmed by Aldevron via a Limulus Amebocyte Lysate assay.
Myocardial Infarction

Author Manuscript

Surgical procedure and induction of acute ischemia were performed as previously
described 21, with more details available in supplemental methods. After induction of
anesthesia by ketamine (20mg/kg) and diazepam (3-5mg/kg), pigs were anesthetized with
isoflurane via a nose mask and intubated, with respiration maintained by a volumecontrolled BonAir mechanical ventilator. A medial sternotomy incision was made for
exposing the heart. The sternotomy was chosen less invasive methods, to allow adequate
view of the entire ischemic surface area for SPY measurements. The pericardium was
removed to expose LAD coronary artery. The LAD was ligated with a 4-0 silk suture below
the second diagonal branch, inducing downstream ischemia, with the suture left in place
following treatment. A radiopaque thread was tied to the silk ligature for marking the LAD
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occlusion site in x-ray imaging. Ischemic areas of the heart wall were identified by perfusion
assessment after the ligation of the LAD by SPY and arteriograms.
Perfusion Assessment
Tissue perfusion through the left ventricular wall was assessed with the SPY® System
(LifeCell Corporation, Branchburg, NJ) prior and immediately after the occlusion of the
LAD. Indocyanine green (IC-Green) fluorescent dye was injected intravenously followed by
SPY scanning of the anterior left ventricular wall for the presence of the dye. Higher
fluorescence intensity was interpreted as higher perfusion. The images collected prior to the
LAD ligation and immediately after the ligation were used to determine the relative loss in
perfusion, the precise location and size of ischemic area in the left ventricle (ischemia of the
septum or the right ventricle are not visible in the field of view of the SPY).

Author Manuscript

Arteriograms

Author Manuscript

X-ray fluoroscopy (Advantx® Systems Fluoroscope, GE Medical Systems, Wauwatosa, WI)
was utilized to view the coronary arteries of the heart prior to LAD occlusion, after the
occlusion, 2 and 7 weeks after myocardial infarction. The femoral artery was accessed via a
cut-down followed by a modified Seldinger technique with a J-tipped angiographic
guidewire (Bard Medical, Covington, GA). A 6-French catheter (Boston Scientific,
Marborough, MA) was guided to the LAD. Arteries were visualized with injection of
Isovue-300 iodine contrast agent (Bracco Diagnostics Inc., Monroe Township, NJ) into the
catheter. A TIMI score of 0, 1, 2 or 3 was assigned to assess flow through the LAD
immediately after the occlusion, at 2 weeks and at 7 weeks. A score of 0 indicated no flow
past occlusion site, a score of 1 indicates slow flow past the occlusion site, but no filling of
the distal regions of the arteries, a score of 2 indicates slow flow past the occlusion with
filling of the distal arteries, and a score of 3 indicates unimpeded flow 22. Arteriograms
performed prior to occlusion and after 7 weeks were compared to assess angiogenesis at the
macroscopic level. The number of animals with new vessels was recorded along with the
vessel length and compared among different experimental groups.
Gene Electrotransfer

Author Manuscript

Gene electrotransfer, plasmid DNA injection only, or sham injection of saline were
administered following SPY perfusion assessment, within an hour of LAD occlusion. This
time point was chosen to minimize stress to the animals, by performing only one invasive,
open-heart procedure and avoiding separate surgeries for LAD occlusion and GET
treatment. Four sites bordering ischemia were selected for GET. A 7mm, 4 needle (5 mm
electrode gap) penetrating electrode with an injection port was used for DNA delivery to the
heart as previously described 20, 21. For each treatment site, the electrode was placed on the
surface of the myocardium, with electrode needles penetrating into the myocardium to 7mm.
A hypodermic needle was used to inject 100μl of plasmid DNA encoding VEGF-A
(pVEGF-A) in saline at 2mg/ml, centrally between the electrode needles through the
injection port. The hypodermic needle was withdrawn, to prevent electrical interference. An
electric field was established between and around the electrode needles with applied voltage
to accomplish electroporation and DNA delivery at the treatment site. Our custom-built
pulse generator and software continuously captured the echocardiogram (ECG) of the
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animal and enabled synchronizing pulsing with the R-wave of the ECG (Accusync Medical
Research Company, Milford, CT). Each site was immediately pulsed eight times with 20ms
pulses at an amplitude of 60V. Animals randomly assigned to the negative control groups
received either saline injections or plasmid DNA injection without electrotransfer.
Immunofluorescence Staining
Seven weeks post myocardial infarction, animals were euthanized and tissue samples were
collected, fixed in 10% formalin, paraffin embedded and sectioned. Slides were stained for
von Willebrand Factor (vWF) to identify microvasculature with a blood vessel staining kit
(Millipore, Billerica, MA). The number of vessels per field of view was counted and
averaged over 10 randomly selected fields of view within each treatment region.
Experimental groups were then compared based on the average number of vessels for vessel
density.
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Echocardiography
Cardiac ultrasound was performed with a Sonosite 180 Plus SonoHeart Ellite Ultrasound
(Bothell, WA) 21, 23 prior to the occlusion of the LAD, immediately after myocardial
infarction, two weeks after MI and 7 weeks after MI. Two dimensional and M-mode
echocardiography was used to measure left ventricular end-systolic diameter, left ventricular
end-diastolic diameter, left ventricular wall (LVPW) thickness, and intraventricular septum
during systole and diastole. The Teicholz method was used to calculate left ventricular endsystolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), cardiac output
(CO), fractional shortening (FS), stroke volume and ejection fraction (EF) 24.
Enzyme-linked Immunosorbent Assays

Author Manuscript

Blood samples were collected prior to MI, 24 hours post occlusion and at 7 weeks, for
analysis of changes cardiac protein levels. Plasma samples were tested for porcine cardiac
troponin-1 (Kamiya Biomedical, Seattle, WA) and creatine kinase MM (Kamiya
Biomedical, Seattle, WA) according to the ELISA kit manufacturer’s instructions, for
indications of initial myocardial damage and presence of heart failure.
Myocardial Infarct Size Measurements
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At seven weeks, hearts were harvested for infarct size assessment and histological analysis.
Harvested hearts were sectioned into 1cm coronal slices (perpendicular to long axis of the
heart). The slices were incubated with 1% triphenyltetrazolium (TTC) (Sigma-Aldrich, St
Louis, MO) at 37°C for 30 minutes. Each side of each slide was then photographed and the
infarct size was measured using ImageJ software to trace the infarct in each image.
In order to calculate the total volume of the infarct, the area measurement from each side of
individual slices was averaged and multiplied by the thickness of the slice. The total infarct
volume is the sum of individual infarct volumes from each heart slice 25. The total
myocardial infarct volume included measurements from both ventricles and the
intraventricular septum.
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Left ventricular MI surface area was also measured in order to compare the area of left
ventricular ischemia induced by occlusion of the LAD to the area of MI after treatment of
the left ventricle. ImageJ software was used to outline the perimeter of the MI on the
pericardial surface of the left ventricle from each slice. The average from each side of the
slice was multiplied by the thickness of the slice. The sum of areas from each slice was then
used to determine the area of left ventricular MI.
End of Study Euthanasia
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On final day of study, animals were anesthetized as follows. After induction of anesthesia by
ketamine (20mg/kg) and diazepam (3-5mg/kg), pigs were anesthetized with isoflurane via a
nose mask and intubated, with respiration maintained by a volume-controlled BonAir
mechanical ventilator. A final arteriogram was performed followed by sternotomy as
described above. Following final assessment of perfusion by SPY procedure, animal was
euthanized by an intracardiac injection of 5 ml of fatal plus.
Statistical Analyses
All quantitative data with calculated means were compared using a one-way or two-way
analysis of variance (ANOVA) with p<0.05 considered to be statistically significant. For
ANOVA analysis yielding statistically significant differences, the Tukey’s multiple
comparisons test was performed to determine which data sets were significantly different.
All quantitative data was reported with the standard error of the mean (SEM). All
proportions were compared with the Chi-Square test for proportions, with p<0.05 considered
significant.
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Figure 1. Permanent ischemia was induced via LAD occlusion
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A) TIMI flow index drops significantly after occlusion, with no significant difference in
TIMI between treatment groups (Two-way ANOVA and Tukey’s multiple comparisons test,
alpha=0.05, P = <0.0001). B) SPY based measurement of ischemic surface area of the left
ventricle indicates consistent occlusion between treatment groups, with no significant
difference in ischemic area (One-way ANOVA, alpha = 0.05, P=0.6388). C) SPY based
measurement of drop in perfusion in the ischemic area of the left ventricle indicates a
consistent reduction in perfusion, with GET group receiving a slightly larger drop in
perfusion than the IO group (One-way ANOVA, Tukey’s multiple comparisons test
alpha=0.05, P=0.0012).
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Figure 2. GET of VEGF-A has no deleterious effects on survival or heart performance over 7
weeks post MI and gene delivery

A) Kaplan-Meier Survival curve with no significant difference between the groups (Logrank
test for trend, P=0.4639), B) Ejection fraction (P=0.9240), C) Cardiac Output (P=0.5603),
D) Fractional Shortening(P=0.3775), E) Left ventricular end systolic volume (P=0.5603), F)
Left Ventricular end diastolic volume(P=0.92), with no significant difference between
treatment groups based on echocardiographic analysis (Two-way ANOVA and Tukey’s
multiple comparison test, alpha=0.05)
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Figure 3. GET of pVEGF-A induces angiogenesis in ischemic myocardium at treatment sites
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A) Arteriograms of GET and IO animals, before occlusion, immediately after occlusion and
7 weeks after occlusion, with new arteries visible in the GET heart. *LAD occlusion site, red
arrows point to new vessels. B) The proportion of hearts with new arteries visible via
arteriogram 2 (P=0.152313) and 7 weeks (P=0.243917) after treatment is higher in hearts
treated with GET of pVEGF-A (Chi-square test). C) vWF staining for blood vessels at a
treatment site of GET of pVEGF-A seven weeks after MI and treatment. D) Blood vessel
density at treatment sites seven weeks after MI and treatment is not significantly different
between treatment groups on a microscopic level (One-way ANOVA, alpha=0.05,
P=0.9704).
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Figure 4. Myocardial infarct size is reduced at GET of pVEGF treatment sites 7 weeks post
treatment
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A) Infarct area to ischemic area ratio is significantly lower in GET treated left ventricles
than in Sham control group, (One-way ANOVA, and Tukey’s multiple comparison test,
alpha=0.05, p=0.0349), B) Total myocardial infarct size including untreated septum and
untreated right ventricle, with no significant differences between the groups (One-way
ANOVA, alpha=0.05, P=0.2028).
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